ATE194598T1 - In der therapie verwendbare chinolin- und chinazolinverbindungen - Google Patents

In der therapie verwendbare chinolin- und chinazolinverbindungen

Info

Publication number
ATE194598T1
ATE194598T1 AT96943954T AT96943954T ATE194598T1 AT E194598 T1 ATE194598 T1 AT E194598T1 AT 96943954 T AT96943954 T AT 96943954T AT 96943954 T AT96943954 T AT 96943954T AT E194598 T1 ATE194598 T1 AT E194598T1
Authority
AT
Austria
Prior art keywords
quinoline
therapy
quinazoline compounds
compounds usable
usable
Prior art date
Application number
AT96943954T
Other languages
English (en)
Inventor
Alan John Collis
David Nathan Abraham Fox
Julie Newman
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of ATE194598T1 publication Critical patent/ATE194598T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
AT96943954T 1995-12-23 1996-12-05 In der therapie verwendbare chinolin- und chinazolinverbindungen ATE194598T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526546.8A GB9526546D0 (en) 1995-12-23 1995-12-23 Compounds useful in therapy
PCT/EP1996/005609 WO1997023462A1 (en) 1995-12-23 1996-12-05 Quinoline and quinazoline compounds useful in therapy

Publications (1)

Publication Number Publication Date
ATE194598T1 true ATE194598T1 (de) 2000-07-15

Family

ID=10786091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943954T ATE194598T1 (de) 1995-12-23 1996-12-05 In der therapie verwendbare chinolin- und chinazolinverbindungen

Country Status (34)

Country Link
US (3) US6103738A (de)
EP (1) EP0877734B1 (de)
JP (1) JP3070958B2 (de)
KR (1) KR19990076693A (de)
AP (1) AP715A (de)
AR (1) AR005166A1 (de)
AT (1) ATE194598T1 (de)
AU (1) AU708979B2 (de)
BG (1) BG102559A (de)
BR (1) BR9612263A (de)
CA (1) CA2236814C (de)
CO (1) CO4480106A1 (de)
CZ (1) CZ197698A3 (de)
DE (1) DE69609353T2 (de)
DK (1) DK0877734T3 (de)
ES (1) ES2151192T3 (de)
GB (1) GB9526546D0 (de)
GR (1) GR3034225T3 (de)
HN (1) HN1996000082A (de)
HR (1) HRP960616A2 (de)
HU (1) HUP9903560A3 (de)
IS (1) IS4731A (de)
MA (1) MA26414A1 (de)
NO (1) NO982913L (de)
NZ (1) NZ325248A (de)
OA (1) OA10703A (de)
PL (1) PL327610A1 (de)
PT (1) PT877734E (de)
SK (1) SK81698A3 (de)
TN (1) TNSN96161A1 (de)
TR (1) TR199801195T2 (de)
WO (1) WO1997023462A1 (de)
YU (1) YU68896A (de)
ZA (1) ZA9610784B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
EP1315714B1 (de) * 2000-08-31 2005-11-09 F. Hoffmann-La Roche Ag Chinazolin-derivate als alpha-1 adrenerge antagonisten
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
WO2002053558A1 (en) * 2001-01-02 2002-07-11 F.Hoffman-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
EP1556381B1 (de) 2002-09-26 2008-02-20 Pfizer Limited Pyrazolamide zur behandlung von hiv-infektionen
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
EP2210607B1 (de) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9114194B2 (en) * 2006-05-12 2015-08-25 W. L. Gore & Associates, Inc. Immobilized biologically active entities having high biological activity following mechanical manipulation
US8986713B2 (en) * 2006-05-12 2015-03-24 W. L. Gore & Associates, Inc. Medical device capable of being compacted and expanded having anti-thrombin III binding activity
US20080279909A1 (en) * 2006-05-12 2008-11-13 Cleek Robert L Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization
US8496953B2 (en) * 2006-05-12 2013-07-30 W. L. Gore & Associates, Inc. Immobilized biologically active entities having a high degree of biological activity following sterilization
US8021677B2 (en) 2006-05-12 2011-09-20 Gore Enterprise Holdings, Inc. Immobilized biologically active entities having a high degree of biological activity
SG179418A1 (en) * 2007-03-14 2012-04-27 Exelixis Patent Co Llc Inhibitors of the hedgehog pathway
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
KR101337163B1 (ko) 2008-11-14 2013-12-05 에프. 호프만-라 로슈 아게 Nk3 수용체 길항제로서 퀴나졸린 유도체
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
AU2010227311B2 (en) * 2009-03-23 2014-06-05 Cipla Limited Process for the preparation of doxazosin and salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA021113B1 (ru) * 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
US8591932B2 (en) * 2009-09-17 2013-11-26 W. L. Gore & Associates, Inc. Heparin entities and methods of use
ES2955183T3 (es) 2011-03-11 2023-11-29 Gore & Ass Mejoras para las entidades biológicas inmovilizadas
WO2013043255A1 (en) * 2011-09-21 2013-03-28 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
EP2819670A1 (de) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmazeutische zusammensetzung und verabreichung davon
SG11201607973XA (en) * 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) * 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79603B (de) * 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
US20030220332A1 (en) 2003-11-27
MA26414A1 (fr) 2004-12-20
HN1996000082A (es) 1997-06-30
AP9600900A0 (en) 1997-01-31
SK81698A3 (en) 2000-04-10
GB9526546D0 (en) 1996-02-28
US6750214B2 (en) 2004-06-15
GR3034225T3 (en) 2000-12-29
NO982913L (no) 1998-07-30
ES2151192T3 (es) 2000-12-16
AU1371997A (en) 1997-07-17
WO1997023462A1 (en) 1997-07-03
AP715A (en) 1998-12-30
OA10703A (en) 2002-11-28
HUP9903560A3 (en) 2000-07-28
DE69609353D1 (de) 2000-08-17
YU68896A (sh) 1999-07-28
JPH11501668A (ja) 1999-02-09
US6642242B2 (en) 2003-11-04
EP0877734A1 (de) 1998-11-18
HRP960616A2 (en) 1998-06-30
DK0877734T3 (da) 2000-11-20
JP3070958B2 (ja) 2000-07-31
IS4731A (is) 1998-04-29
TNSN96161A1 (fr) 2005-03-15
EP0877734B1 (de) 2000-07-12
CA2236814A1 (en) 1997-07-03
ZA9610784B (en) 1998-06-22
PL327610A1 (en) 1998-12-21
CZ197698A3 (cs) 1999-03-17
TR199801195T2 (xx) 1998-10-21
NZ325248A (en) 1999-09-29
DE69609353T2 (de) 2000-12-07
CO4480106A1 (es) 1997-07-09
PT877734E (pt) 2000-12-29
AR005166A1 (es) 1999-04-14
US6103738A (en) 2000-08-15
BR9612263A (pt) 1999-07-13
KR19990076693A (ko) 1999-10-15
US20020049322A1 (en) 2002-04-25
BG102559A (en) 1999-03-31
CA2236814C (en) 2001-09-18
NO982913D0 (no) 1998-06-22
HUP9903560A2 (hu) 2000-05-28
AU708979B2 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
ATE194598T1 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
HRP980010B1 (en) Quinoline and quinazoline compounds useful in therapy
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
EE9700209A (et) Dihüdropürimidiinid ja nende kasutamine
FR11C0020I2 (fr) Dérives difluoroprostaglandines et leur application
TR199501305A2 (tr) Heterosiklik bilesikler ve bunlarin hazirlanmasi ve kullanimi
FI972546L (fi) Ristiinsidotut mikropartikkelit ja niiden käyttö hoitavina apuaineina
FI970990A7 (fi) Syövän toteaminen ja hoito
FI961758A7 (fi) Kinatsoliinijohdannainen
AU1886197A (en) Quinolones and their therapeutic use
ID18679A (id) Penggunaan terapi lanjutan
FI952656A0 (fi) Foerfarande och anordning vid pulsmaetning av en person
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
FI964936L (fi) Bentsopyraaneja ja niiden käyttö terapeuttisina aineina
KR970702861A (ko) 포르포시아닌 및 cnc-확장된 포르피린(porphocyanine and cnc-expanded porphyrins)
GB9712761D0 (en) Quinolines and their therapeutic use
DE69620243D1 (de) Haupt- und nebenstromfilter
FI971193L (fi) Hoidossa käyttökelpoisia kinoksaliinijohdannaisia
FI954680L (fi) Kinoloni- ja naftyridonikarboksyylihappojohdannaiset
LV11328A (lv) 1-(2-fluorciklopropil)-hinolona un naftiridonkarbonskabes atvasinajumi
ZA9710000B (en) Quinolines and their therapeutic use
SE9604300D0 (sv) Therapeutical use and method
GB9611898D0 (en) Quinolones and their therapeutic use
GB9702929D0 (en) Quinolones and their therapeutic use
GB9702933D0 (en) Quinolones and their therapeutic use

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee